The Truth about Drug Companies: How They Deceive Us and What to Do about It

By T. Cymet. 2006

649 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Innovation and Firm Growth: Is R&D Worth It? (2012, background): “While large firms have been heavily criticized for their low R&D productivity and the lack of truly innovative drug discoveries (Angell, 2005), there has not been much systematic evidence indicating the economic returns to R&D.”
Public financing of innovation: new questions (2017, background): “Among those agencies mentioned above, the National Institutes of Health (NIH) have spent billions on health R&D, stimulating what later became the biotechnology revolution in both periods of boom and bust.”
Mixing Business With Politics: A Meta-Analysis of the Antecedents and Outcomes of Corporate Political Activity (2011, background): “Now a major source of funding for the FDA, the regulatory agency has now become dependent on the regulated industry for funding through successful CPA (Angell, 2004).”
The Entrepreneurial State (2013, unknown): “Since 2000, the NIH has invested more than $400 billion (2013 dollars) in the biotech-pharma knowledge base, and $29 billion in 2013 alone.”
From the gene to the globe: Extracting rents based on intellectual property monopolies (2007, background): “Xoma, which had sold the property rights on royalties, was left empty-handed, apart from the above-mentioned 17 million USD (Robbins-Roth, 2000: 159, 216; Xoma, 1998).”